Review
Medicine, General & Internal
Quirino Lai, Gianluca Mennini, Francesco Giovanardi, Massimo Rossi, Edoardo G. Giannini
Summary: Prophylaxis with HBIG is effective in preventing post-LT HBV recurrence, and its combination with NUC provides the best protection. Further studies on high genetic barrier-to-recurrence NUC and protocols with definitive use of HBIG are needed to optimize prophylactic strategies.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Gastroenterology & Hepatology
Jia-Horng Kao, Wen-Juei Jeng, Qin Ning, Tung-Hung Su, Tai-Chung Tseng, Yoshiyuki Ueno, Man-Fung Yuen
Summary: Chronic HBV infection is currently incurable and long-term treatment with NAs can reduce complications, but stopping treatment may lead to virological relapse and adverse outcomes. Close monitoring and personalized follow-up strategies are essential for a safe cessation of NA therapy.
HEPATOLOGY INTERNATIONAL
(2021)
Article
Immunology
Tong Yu, Miaoqu Zhang, Hanyue Zhang, Jianming Zheng, Chuan Shen, Ning Jiang, Lei Zou, Jing Wang, Yiqi Yu, Qiran Zhang, Shuili Yu, Yanfang Huang, Yuxian Huang, Jiming Zhang, Chao Qiu, Wenhong Zhang, Zhefeng Meng
Summary: Our findings indicate that residual HBV replication persists in chronic hepatitis B patients who have been successfully treated with nucleos(t)ide analogues. It may take many years or even lifelong treatment to effectively eliminate HBV, considering the estimated half-life of cccDNA.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Immunology
Shi Liu, Rui Deng, Bin Zhou, Xieer Liang, Zhihong Liu, Jie Peng, Jinjun Chen, Yuanping Zhou, Yabing Guo, Yongpeng Chen, Wanying Li, Sheng Shen, Xingyu Lu, Siru Zhao, Xingmei Liao, Hongyan Liang, Yu Lan, Jinlin Hou, Rong Fan, Jian Sun
Summary: High levels of serum HBV RNA are associated with increased risk of hepatocellular carcinoma in chronic hepatitis B patients. Achieving undetectable HBV RNA may be a valuable endpoint of antiviral treatment.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Review
Pharmacology & Pharmacy
Issam Tout, Pietro Lampertico, Thomas Berg, Tarik Asselah
Summary: Long-term treatment with NAs is the current first line therapy for patients with CHB, preventing disease progression and liver failure. However, low rates of on-therapy functional cure hinder many patients from stopping NA therapy, leading to the need for lifelong treatment.
ANTIVIRAL RESEARCH
(2021)
Article
Gastroenterology & Hepatology
Yao-Chun Hsu, Yi-Hsian Lin, Teng-Yu Lee, Mindie H. H. Nguyen, Cheng-Hao Tseng, Hsiu J. J. Ho, Feng-Yu Kao, Jaw-Town Lin, Chen-Yi Wu, Chun-Ying Wu
Summary: This study aimed to quantify the incidence of severe hepatitis flares following NUC cessation in everyday clinical practice. The study found that approximately 1-2% of patients with chronic hepatitis B (CHB) will experience severe flares with hepatic decompensation after discontinuing NUC therapy. Significant risk factors for flares include cirrhosis, portal hypertension, older age, and male sex. Therefore, the study recommends against routine cessation of NUC therapy in clinical care.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Biochemistry & Molecular Biology
Noriaki Orita, Kazunori Kawaguchi, Masao Honda, Tetsuhiro Shimode, Nozomu Hayakawa, Takeshi Terashima, Takuya Komura, Masashi Nishikawa, Rika Horii, Kouki Nio, Tetsuro Shimakami, Hajime Takatori, Kuniaki Arai, Yoshio Sakai, Tatsuya Yamashita, Eishiro Mizukoshi, Shuichi Kaneko, Takashi Kagaya, Taro Yamashita
Summary: There is an association between HBV-related HCC incidence and AKR1B10 under nucleos(t)ide analogues (NAs) treatment, particularly with the use of lamivudine and adefovir pivotil. Serum AKR1B10 levels are higher in HCC cases under NA treatment and are not influenced by entecavir or tenofovir alafenamide. In-vitro examination shows that entecavir and tenofovir reduce AKR1B10 expression.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2023)
Editorial Material
Gastroenterology & Hepatology
Ritsuzo Kozuka, Masaru Enomoto, Norifumi Kawada
Summary: This article is linked to the paper by Lee et al. To view the article, please visit the provided link.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Virology
Yanhua Tang, Rong Fan, Zhixian Lan, Qing Xie, Jiping Zhang, Xieer Liang, Hao Wang, Deming Tan, Jun Cheng, Shijun Chen, Qin Ning, Xuefan Bai, Min Xu, Xinyue Chen, Junqi Niu, Junping Shi, Hong Ren, Zhiliang Gao, Maorong Wang, Xiaoguang Dou, Jinlin Hou, Jian Sun
Summary: This study found that the percentage of chronic hepatitis B (CHB) patients with concurrent nonalcoholic fatty liver disease (NAFLD) increased during antiviral therapy, and patients with new-onset and sustained NAFLD showed poorer treatment outcomes, including lower rates of biochemical response and fibrosis improvement.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Virology
Hao Liao, He Zhang, Jinman Shao, Xiaoyong Li, Wei V. Zheng, Le Li, Guangxin Yu, Lanlan Si, Tao Zhou, Zengtao Yao, Jiuzeng Dai, Dongping Xu, Guanxun Cheng, Jiuxin Qu, Yan Liu, Junhui Chen, Fengmin Lu
Summary: This study aimed to investigate the dynamic changes of serum hepatitis B virus (HBV) RNA levels and the quasispecies of HBV RNA virus-like particles in nucleos(t)ide analogues (NAs)-experienced chronic hepatitis B patients with NAs-resistant mutations and their effects on NAs resistance. The results showed that serum HBV RNA can reflect virological breakthrough and rebound earlier than HBV DNA in some patients. However, there are limitations in the detection of serum HBV RNA levels and drug-resistant mutations compared to serum HBV DNA.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Medicine, General & Internal
Jing Wen Chen, Xiong Yue Cao, Xun Qi, Ji Ming Zhang
Summary: This study aimed to explore the effects of three nucleos(t)ide analogues on lipid levels. The results showed that patients in the TDF group had lower blood lipid levels compared to the TAF and ETV groups. Factors associated with hyperlipidemia included age, sex, body mass index, and different treatments.
Article
Gastroenterology & Hepatology
Spilios Manolakopoulos, Hariklia Kranidioti, Anastasia Kourikou, Melanie-Maria Deutsch, Christos Triantos, Chrysostomos Tsolias, Emanuel K. Manesis, Nicoletta Mathou, Alexandra Alexopoulou, Emilia Hadziyannis, George Papatheodoridis
Summary: The study showed that it is safe to discontinue nucleos(t)ide analogues therapy in non-cirrhotic patients with HBeAg-negative chronic hepatitis B. Over a median follow-up of more than 5 years, half of the patients remained without retreatment, with a substantial proportion achieving functional cure.
LIVER INTERNATIONAL
(2021)
Article
Immunology
Peipei Wang, Zhishuo Mo, Ying Zhang, Chunxia Guo, Trevor Kudzai Chikede, Dabiao Chen, Ziying Lei, Zhiliang Gao, Qian Zhang, Qiaoxia Tong
Summary: This study investigates the changes in cytokines during nucleos(t)ide analogues and peginterferon-alpha therapy and their impact on the HBsAg serologic response. It found that IL-5 may be used as a biomarker for HBsAg seroclearance in patients with chronic hepatitis B treated with nucleos(t)ide analogues combined with peginterferon-alpha. This finding helps to develop a better understanding of the immune pathogenesis of chronic HBV infection.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Gastroenterology & Hepatology
Xieer Liang, Qing Xie, Jia Shang, Hong Tang, Min Xu, Qinghua Meng, Jiming Zhang, Pujun Gao, Jifang Sheng, Hao Wang, Jidong Jia, Guiqiang Wang, Shunquan Wu, Jingna Ping, Jinlin Hou
Summary: This study investigated the efficacy and safety of Tenofovir disoproxil fumarate (TDF) in Chinese patients with chronic hepatitis B (CHB) infection after treatment failure with multiple nucleos(t)ide analogues (NAs). The results showed that TDF is efficacious and safe in patients with CHB who have failed multiple NA treatments.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Machiko Umemura, Koji Ogawa, Kenichi Morikawa, Akinori Kubo, Yoshimasa Tokuchi, Ren Yamada, Takashi Kitagataya, Taku Shigesawa, Tomoe Shimazaki, Megumi Kimura, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Naoki Kawagishi, Takaaki Izumi, Masato Nakai, Takuya Sho, Goki Suda, Mitsuteru Natsuizaka, Kota Ono, Kazumoto Murata, Masaya Sugiyama, Masashi Mizokami, Naoya Sakamoto
Summary: This study investigated the effects of nucleos(t)ide analogs (NAs) on hepatitis B surface antigen (HBsAg) reduction and interferon-lambda3 (IFN-lambda 3) induction in chronic hepatitis B (CHB) patients. The results showed that nucleotide analog (ADV/TDF) treatment reduced HBsAg levels greater compared with nucleoside analog (ETV) in parallel with IFN-lambda 3 induction.
HEPATOLOGY RESEARCH
(2022)